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Chronic inflammatory diseases such as chronic 
infection, cancer, and heart failure are often 
associated with adipose tissue loss (Delano and 
Moldawer, 2006). Adipose tissue loss in the 
setting of chronic inflammatory diseases could 
ultimately represent a major health problem 
because of associated comorbidities such as 
weakness, fatigue, and impaired immunity. Loss 
of adipose tissue is ultimately caused by an 
imbalance between food intake and energy 
expenditure. Although food intake is often re-
duced in patients with chronic inflammatory 
diseases, these patients exhibit a persistent state 
of inappropriately high metabolic rate, and 
this substantially contributes to their adipose 
loss (Delano and Moldawer, 2006). However, 
the link between chronic inflammation, tissue 
metabolism, and enhanced energy expenditure 
in this state of chronic hypermetabolism is not 
fully understood.
Among chronic inflammatory diseases, he-
matological malignancies such as leukemias and 
myeloproliferative disorders are also associated 
with adipose tissue loss (Dingli et al., 2004). In 
humans, among the most common activating 
mutations in myeloid malignancies are muta-
tions in the FMS-like tyrosine kinase 3 (Flt3) 
gene, which occur in 30% of cases of acute 
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A high metabolic rate in myeloproliferative disorders is a common complication of 
neoplasms, but the underlying mechanisms are incompletely understood. Using three 
different mouse models of myeloproliferative disorders, including mice with defective 
cholesterol efflux pathways and two models based on expression of human leukemia dis-
ease alleles, we uncovered a mechanism by which proliferating and inflammatory myeloid 
cells take up and oxidize glucose during the feeding period, contributing to energy dissipa-
tion and subsequent loss of adipose mass. In vivo, lentiviral inhibition of Glut1 by shRNA 
prevented myeloproliferation and adipose tissue loss in mice with defective cholesterol 
efflux pathway in leukocytes. Thus, Glut1 was necessary to sustain proliferation and poten-
tially divert glucose from fat storage. We also showed that overexpression of the human 
ApoA-I transgene to raise high-density lipoprotein (HDL) levels decreased Glut1 expression, 
dampened myeloproliferation, and prevented fat loss. These experiments suggest that 
inhibition of Glut-1 and HDL cholesterol–raising therapies could provide novel therapeutic 
approaches to treat the energy imbalance observed in myeloproliferative disorders.
© 2013 Gautier et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
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controls by indirect calorimetry. No significant changes in 
daily food intake, energy expenditure, or locomotor activity 
were observed in these mice (Table 1). Similar fat and cho-
lesterol absorption and bile acid excretion were also observed 
in Abca1/Abcg1/ mice (not depicted). However, Abca1/ 
Abcg1/ BM transplanted mice exhibited a higher respira-
tory quotient (RQ) during the feeding period (dark phase; 
Fig. 1 D), reflecting an 20% increase in glucose oxidation 
(Fig. 1 E) and exhibited hypoglycemia (Table 1). Injection i.p. 
of a glucose bolus also revealed faster glucose utilization 
in Abca1/Abcg1/ BM transplanted mice compared with 
WT transplanted controls (Fig. 1 F). We next examined the 
uptake of the radiolabeled d-glucose analogue 2-[14C]-
deoxyglucose (2-[14C]-DG) in Abca1/Abcg1/ BM trans-
planted mice in the fed state. No significant changes were 
observed in the total uptake of 2-[14C]-DG in the skeletal 
muscle and brain (Fig. 1 G), whereas, in line with their re-
duced fat mass, total 2-[14C]-DG incorporation was reduced 
in their adipose tissue (Fig. 1 G). In contrast, the total uptake 
of 2-[14C]-DG was increased by two- to threefold in the 
heart, lung, spleen, and BM of these mice (Fig. 1 G) and by 
1.5-fold when expressed as the rate constant for net tissue 
uptake of 2-[14C]-DG uptake (Fig. 1 H). Thus, we showed 
that Abca1/Abcg1/ BM transplanted mice have increased 
propensity to clear and use glucose.
Inflammation diverts glucose from fat storage by promoting 
adipose tissue insulin resistance in Abca1/Abcg1/  
BM transplanted mice
Consistent with their myeloproliferative disorder, Abca1/ 
Abcg1/ BM chimeras exhibited a chronic inflammatory state 
as reflected by a threefold increase in plasma TNF levels 
(Table 1). Microscopic examination of the adipose tissue of 
Abca1/Abcg1/ BM transplanted mice revealed an in-
creased inflammatory infiltrate reflected by crown-like struc-
tures (Fig. 2 A). Because infiltrated leukocytes are a hallmark 
of insulin resistance in adipose tissue (Lumeng and Saltiel, 
2011; Odegaard and Chawla, 2011), we wondered whether 
the adipose tissue infiltration observed in Abca1/Abcg1/ 
BM chimeras would promote local insulin resistance and 
contribute to their reduced adipose tissue glucose uptake. To 
address this question, a bolus of insulin was injected into WT 
and Abca1/Abcg1/ BM transplanted mice, and hallmarks 
of insulin signaling (AKT phosphorylation and GLUT4 ad-
dressing to the cell membrane) were assessed. Western blot 
analysis revealed reduced GLUT4 translocation from the 
low-density microsome fraction to the plasma membrane in 
response to insulin in the adipose tissue of Abca1/Abcg1/ 
BM transplanted mice (Fig. 2 B). This was associated with 
reduced AKT phosphorylation, suggesting insulin resistance 
in adipocytes is secondary to local inflammatory cell infil-
tration (Fig. 2 B). Accordingly, microscopic analysis of iso-
lated adipocytes revealed smaller adipocytes in WT recipients 
transplanted with Abca1/Abcg1/ BM cells (Fig. 2 A and 
Table 1), whereas adipocyte cell numbers were comparable 
with controls (Table 1). Finally, depletion of Ly6C/G+ 
thrombopoietin receptor (proto-oncogene c-Mpl) observed 
in 5–10% of patients with myelofibrosis. These mutations 
confer a fully penetrant myeloproliferative disorder in mice 
(Kelly et al., 2002; Pikman et al., 2006), providing a useful 
tool for studying the mechanism of adipose tissue loss associ-
ated with myeloproliferative disorders.
We have recently shown that mice lacking the cholesterol 
efflux transporters ABCA1 and ABCG1 develop massive ex-
pansion and proliferation of hematopoietic stem and progeni-
tor cells, marked monocytosis, neutrophilia, and infiltration 
of various organs with myeloid cells, resembling a classical 
myeloproliferative disorder (Hansson and Björkholm, 2010; 
Yvan-Charvet et al., 2010). As we noticed a dramatic loss of 
adipose tissue in Abca1/Abcg1/ BM chimeras, we hy-
pothesized that the myeloproliferative disorder of these mice 
might be responsible for their wasting syndrome and pro-
ceeded to investigate the underlying mechanisms.
RESULTS
Lack of ABCA1 and ABCG1 in hematopoietic cells  
promotes adipose tissue atrophy
Determination of the fat and muscle mass of irradiated WT 
recipients transplanted with Abca1/Abcg1/ BM cells fed 
a chow diet revealed not only absence of adipose tissue 
growth but also reduced epididymal fat mass at 24 wk after 
reconstitution compared with controls (Fig. 1 A). Gastroc-
nemius muscle loss was also observed 30 wk after reconstitu-
tion in these mice (Fig. 1 B). Subcutaneous and retroperitoneal 
adipose depots were also decreased by more than threefold at 
24 wk after reconstitution in Abca1/Abcg1/ BM chime-
ras, consistent with their reduced plasma leptin levels (Table 1). 
To test whether the adipose tissue atrophy of these mice was 
a direct consequence of their defective hematopoietic com-
partment and myeloproliferative syndrome (Yvan-Charvet 
et al., 2010), we generated hematopoietic stem cell (HSC)–
specific chimeric animals by transplanting lethally irradi-
ated WT recipients with purified WT or Abca1/Abcg1/ 
HSCs (LinSca+cKit+, LSK fraction). Mice transplanted 
with Abca1/Abcg1/ LSK cells reproduced the three-
fold increase in the Gr-1hi/CD11bhi blood myeloid popu-
lation observed in Abca1/Abcg1/ BM transplanted mice 
(Yvan-Charvet et al., 2010) and exhibited a twofold re-
duction in fat mass 12 wk after reconstitution (Fig. 1 A). 
Similar findings were observed in mice with specific knock-
out of these transporters in the hematopoietic lineage 
(Mx1-Cre Abca1fl/flAbcg1fl/fl) 10 wk after injections of 
PolyI:C to excise the STOP codon that prevents the expres-
sion of the cre recombinase (Fig. 1 C). Together, these obser-
vations revealed that the expansion of adipose tissue is 
severely compromised in mice lacking ABCA1 and ABCG1 
in their hematopoietic system.
ABCA1 and ABCG1 deficiency in leukocytes  
impacts glucose homeostasis
We next compared the metabolic characteristics of chow-fed 
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Figure 1. Adipose tissue atrophy and enhanced glucose utilization in Abca1/Abcg1/ BM chimeras. (A) Epididymal adipose tissue of WT 
recipient mice transplanted with WT or Abca1/Abcg1/ BM cells or WT and Abca1/Abcg1/ HSC (LinSca+cKit+, LSK fraction) transplanted mice. 
(B) Gastrocnemius skeletal muscle mass of these mice. (C) Epididymal fat mass in mice with specific knockout of these transporters in the hematopoietic 
lineage (Mx1-Cre Abca1fl/flAbcg1fl/fl) 10 wk after three injections of 15 mg/kg PolyI:C to excise the STOP codon. (D and E) RQ (D) and glucose oxidation 
efficiency (E) measured by indirect calorimetry in chow-fed WT and Abca1/Abcg1/ BM transplanted (BMT) mice 10 wk after reconstitution. (F) Glucose 
tolerance test was performed i.p. on chow-fed WT and Abca1/Abcg1/ BM transplanted mice 12 wk after reconstitution. Blood glucose con-
centrations were measured at the indicate time points. (G and H) Tissue uptake (G) and rate constant of 2-[14C]-DG (H) in 24-wk-old chow-fed WT and 
Abca1/Abcg1/ BM transplanted mice at the end of the study period (40 min after i.v. injection of the radiolabeled tracer). All results are means ± 
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we next assessed the mRNA expression levels of several 
members of this family, namely Glut1, Glut2, Glut3, Glut4, 
and Glut6. Abca1/Abcg1/ BM cells exhibited a two-
fold up-regulation of the glucose transporter Glut1 mRNA 
expression, which was also the most highly expressed Glut 
member in leukocytes (Fig. 3 C). Flow cytometry analysis 
showed a 30% increase in the cell surface expression of 
Glut1 in vivo in Abca1/Abcg1/ CD45+ leukocytes (not 
depicted), including monocytes, neutrophils, and lympho-
cytes (Fig. 3 D), and this correlated with increased mito-
chondrial membrane potential (Fig. 3 E). Together, these 
findings show that leukocytes have a major role in glucose 
uptake in Abca1/Abcg1/ BM transplanted mice exhib-
iting a myeloproliferative syndrome. This resulted in en-
hanced whole body glucose oxidation that could explain the 
increased energy dissipation in these mice.
Signaling via the IL-3/GM-CSF receptor common -subunit 
enhances the expression of Glut1 and glycolytic enzymes  
in proliferating Abca1/Abcg1/ leukocytes
We next set out to better understand the mechanism leading 
to increased glucose uptake in Abca1/Abcg1/ leukocytes. 
Up-regulation of Glut-1 by oncogenes such as Ras or Src has 
been reported (Flier et al., 1987), and we recently showed 
enhanced Ras-Erk signaling in Abca1/Abcg1/ BM cells 
at basal state and in response to the hematopoietic growth 
factors IL-3 and GM-CSF (Yvan-Charvet et al., 2010). 
Therefore, we investigated the expression of Glut1 in re-
sponse to IL-3 in BM leukocytes. As shown in Fig. 3 F, Glut1 
mRNA levels were increased upon stimulation with IL-3 in 
WT BM cells and were further increased in Abca1/Abcg1/ 
cells. Inhibition of the Ras signaling pathway using a farnesyl 
transferase inhibitor, known to prevent the anchorage of Ras 
myeloid cells with the anti–granulocyte receptor-1 (Gr-1) 
antibody RB6-8C5 partially reversed the reduced glucose 
uptake in the adipose tissue of Abca1/Abcg1/ mice (not 
depicted). Together, these results indicate that myeloprolif-
eration and associated adipose tissue infiltration compromise 
adipose tissue function and likely contribute to the loss of fat 
in Abca1/Abcg1/ BM transplanted mice. Moreover, these 
findings revealed that Abca1/Abcg1/ BM chimeras can 
efficiently clear glucose despite being insulin resistant.
Glucose consumption by proliferating myeloid cells 
contributes to whole body glucose dissipation  
in Abca1/Abcg1/ BM transplanted mice
Although local inflammation promoted adipose tissue in-
sulin resistance, this could not explain the enhanced glucose 
uptake by noninsulin-sensitive tissues (Fig. 1 G) contrib-
uting to enhanced whole body glucose oxidation during 
the feeding period (Fig. 1 E). Because these tissues exhibit 
massive myeloid infiltration in Abca1/Abcg1/ BM trans-
planted mice (Yvan-Charvet et al., 2007; Out et al., 2008), 
we next investigated the uptake of glucose by Abca1/ 
Abcg1/ leukocytes. To estimate glucose utilization by flow 
cytometry, we used the fluorescent d-glucose analogue 
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-
d-glucose (2-NBDG) as a tool that reflects the glucose 
bound to the cells and its uptake. Leukocytes isolated from 
Abca1/Abcg1/ BM revealed a significant 30% increase 
in 2-NBDG staining (Fig. 3 A). This increase was massive 
in monocytes and neutrophils when the increased cell num-
ber was taken into account (Fig. 3 B; Yvan-Charvet et al., 
2010), accounting for the total uptake of 2-[14C]-DG in 
the BM (Fig. 1 G). As glucose uptake depends on the glu-
cose transporter (Glut) family (Herman and Kahn, 2006), 
Table 1. Effect of leukocyte ABCA1 and ABCG1 deficiencies on body weight, plasma leptin levels, subcutaneous and 
retroperitoneal adipose depots, plasma glucose, insulin and TNF levels, epididymal adipose tissue cellularity, and energy metabolism
Metabolic parameters BM transplantation
WT Abca1/Abcg1/
Body weight (g) 27.9 ± 0.9 27.4 ± 0.6
Plasma Leptin (ng/ml) 1.95 ± 0.4 0.7 ± 0.2*
Subcutaneous fat mass (g) 0.52 ± 0.12 0.15 ± 0.03*
Retroperitoneal fat mass (g) 0.28 ± 0.04* 0.09 ± 0.08*
Plasma glucose (g/liter) 2.1 ± 0.1 1.7 ± 0.1*
Plasma Insulin (ng/ml) 7.9 ± 0.8 6.1 ± 1.1
Plasma TNF (pg/ml) 3.1 ± 0.5 7.4 ± 0.6*
Fat cell number (×106) 4.8 ± 0.9 4.6 ± 0.8
Fat cell weight (ng) 119 ± 14* 36 ± 5*
Food intake (g/day) 3.28 ± 0.14 3.33 ± 0.13
Food intake (g/day/g0.75) 0.29 ± 0.01 0.29 ± 0.01
Energy expenditure, EE (W/kg0.75) 6.68 ± 0.25 7.11 ± 0.18
Locomotor activity (counts/14 min) 2,589 ± 544 2,560 ± 499
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not galactose enhanced the proliferation of Abca1/Abcg1/ 
leukocytes to the level of high-glucose DMEM (DMEM 
rich), pointing to a prominent role of the glycolysis pathway 
in cell growth. However, a potential contribution of the pen-
tose phosphate pathway to Abca1/Abcg1/ leukocyte 
proliferation could not be completely excluded from this 
experiment. We next challenged the mitochondria with either 
in the plasma membrane and to inhibit the proliferation of 
Abca1/Abcg1/ BM cells (Yvan-Charvet et al., 2010), 
normalized Glut1 mRNA expression to WT levels (Fig. 3 F). 
Further characterization of signaling pathways downstream 
of the IL-3/GM-CSF receptor common -chain (Chang 
et al., 2003) showed that the phosphoinositide 3-kinase in-
hibitor LY294002 prevented IL-3–induced Glut1 mRNA 
expression in Abca1/Abcg1/ leukocytes (Fig. 3 F), similar 
to the effect of this inhibitor on the proliferation of these cells 
(Yvan-Charvet et al., 2010). Analysis of the rates of [14C]glucose 
oxidation revealed that in basal and IL-3–stimulated condi-
tions, Abca1/Abcg1/ leukocytes exhibited a higher glyco-
lytic rate (Fig. 3 G). This effect was inhibited by removal of 
membrane cholesterol by cyclodextrin (Fig. 3 G), consistent 
with the cholesterol-dependent regulation of IL-3R signal-
ing (Yvan-Charvet et al., 2010). Analysis of genes of the gly-
colytic and lipid synthetic pathways also revealed up-regulation 
of hexokinase 2 (Hk2), phosphofructokinase (PFK), and 
ATP-citrate lyase (ACL) mRNAs in Abca1/Abcg1/ leu-
kocytes that was dependent on the IL-3/GM-CSF receptor 
common -chain signaling pathway (Fig. 3 H). Fumarase 
and succinate dehydrogenase (SDH) mRNA expression was 
also increased in response to IL-3 in Abca1/Abcg1/ leu-
kocytes (Fig. 3 H). Together, our results point to the IL-3/
GM-CSF receptor common -chain/GLUT1 axis as a major 
determinant of the increased glucose uptake observed in 
Abca1/Abcg1/ leukocytes.
Metabolic profiling reveals increased glycolysis  
and oxidative phosphorylation in proliferating  
Abca1/Abcg1/ leukocytes
Further quantification of glycolytic metabolites by LC-MS 
showed higher glucose 6-phosphate/fructose 6-phosphate 
(G6P+F6P) and fructose 1,6-diphosphate (F1,6BP) levels 
in basal and IL-3–stimulated Abca1/Abcg1/ leukocytes 
(Fig. 4 A). Increased citric acid cycle metabolites (citrate, 
isocitrate, succinate, fumarate, and malate) and related mito-
chondrial products (GTP and FAD) were also observed in 
Abca1/Abcg1/ leukocytes under basal and/or IL-3–stim-
ulated conditions (Fig. 4, B and C). Consistent with these 
findings, a higher ATP to ADP ratio was observed in prolif-
erating Abca1/Abcg1/ leukocytes (Fig. 4 D). This was as-
sociated with increased mitochondrial membrane potential 
measured using a fluorescent tetramethylrhodamine ethyl 
ester (TMRE) dye (not depicted) and increased SDH activity 
in Abca1/Abcg1/ leukocytes (Fig. 4 E).
The increased glycolysis in Abca1/Abcg1/ leukocytes  
is required for proliferation
To test whether high levels of glycolysis are required for 
Abca1/Abcg1/ leukocyte proliferation, we next cultured 
cells with media containing galactose or glucose. Galactose 
enters glycolysis through the Leloir pathway, which occurs at 
a significantly lower rate than glucose entry into glycolysis 
(Bustamante and Pedersen, 1977). Fig. 4 F shows that under 
glucose-free DMEM (DMEM poor), addition of glucose but 
Figure 2. Infiltrated leukocytes modulate adipose tissue insulin sen-
sitivity in Abca1/Abcg1/ BM chimeras. (A) Paraffin-embedded serial 
sections obtained from the adipose tissue of WT and Abca1/Abcg1/ 
BM transplanted (BMT) mice fed a chow diet. Representative H&E stain-
ing revealed an extensive myeloid cell infiltrate in Abca1/Abcg1/ 
BM transplanted mice compared with controls. Micrographs of iso-
lated epididymal adipose cells confirmed reduced adipose cell size in 
Abca1/Abcg1/ BM transplanted mice. Data representative of four to 
six animals per group are shown. Bars, 1 mm. (B) Western blot analysis of 
plasma membrane (PM) and low-density microsome (LDM) Glut4, phos-
pho-Akt, and total Akt in the adipose tissue of WT and Abca1/Abcg1/ 
BM transplanted mice after acute i.p. injection of an insulin bolus. Quan-
titative results were obtained from two independent experiments. Values 
are mean ± SEM and expressed as percent expression of PM Glut4 over 
HDM fraction or as arbitrary units (a.u.). *, P < 0.05 versus insulin-injected 








niversity In St. Louis Libraries user on 08 D
ecem
ber 2019
344 HDL and Glut1 in wasting syndrome | Gautier et al.
leukocytes, suggesting the requirement of the pyruvate entry 
into the TCA cycle for proliferation (Fig. 4 G). We next used 
the phosphoserine phosphatase inhibitor DL-AP3 (Hawkinson 
et al., 1996), which blocks the rate-limiting step of the serine 
branched-chain amino acids (i.e., valine, leucine, and isoleu-
cine) or with cysteamine to fuel the tricarboxylic acid (TCA) 
cycle with acetyl-coA or coA, respectively, but these treat-
ments did not increase the proliferation of Abca1/Abcg1/ 
Figure 3. Enhanced glycolytic activity in Abca1/Abcg1/ leukocytes. (A) Ex vivo characterization of the glucose binding and/or uptake in WT 
and Abca1/Abcg1/ BM leukocyte subpopulations (i.e., CD115+ monocytes, CD115GrI+ neutrophils, and TCRb+ lymphocytes) using a fluorescent  
d-glucose analogue (2-NBDG). (B) Glucose uptake normalized by the amount of BM leukocytes. (C) mRNA expression of glucose transporters (Gluts) in 
freshly isolated WT and Abca1/Abcg1/ BM cells. (D) Cell surface expression of Glut1 was also quantified in WT and Abca1/Abcg1/ BM neutro-
phils, monocytes, and lymphocytes. (E) Mitochondrial membrane potential measured by fluorescent TMRE dye. All results are means ± SEM and are repre-
sentative of two independent experiments (n = 5–6 animals per groups). *, P < 0.05 versus controls. MFI, mean fluorescence intensity. (F) Glut1 expression 
after BM cells were treated for 72 h with the indicated growth factors and in the presence or absence of 1 µM farnesyl transferase inhibitor (FTI) or  
10 µM PI3K inhibitor (LY294002). Values were normalized to ribosomal 18S. (G) Effect of IL-3 treatment and cholesterol depletion by cyclodextrin (CD) on 
[14C]glucose conversion into CO2 in WT and Abca1/Abcg1/ BM cells. (H) mRNA expression of Hk2, PFK isoform p (PFKp), ACL, fumarase, and SDH sub-
unit b (SDHb) in WT and Abca1/Abcg1/ BM-derived cells untreated or treated for 72 h with IL-3. Values were normalized to ribosomal 18S. Results 
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biosynthetic pathway (Lunt and Vander Heiden, 2011) but 
also the pyruvate dehydrogenase phosphoserine phosphatases 
(PDPs) known to switch metabolic flux from glycolysis to-
ward oxidative phosphorylation. This treatment prevented 
the enhanced proliferation of Abca1/Abcg1/ leukocytes 
(Fig. 4 G). Because inhibition of serine palmitoyltransferase 
by myriocin, downstream of the serine biosynthetic pathway, 
proportionately inhibited both WT and Abca1/Abcg1/ 
leukocytes (Fig. 4 G), this suggested that the effect of DL-AP3 
was most likely related to inhibition of PDPs. Inhibition 
of diglyceride acyltransferase also proportionately inhibited 
both WT and Abca1/Abcg1/ leukocyte proliferation 
(Fig. 4 G), suggesting that despite enhanced lipid synthesis 
(Fig. 5 A), neither ceramide or triglyceride biosynthesis 
was the limiting step for the proliferation of these cells.
Proliferating Abca1/Abcg1/ leukocytes exhibit 
enhanced mitochondrial metabolism
To better understand the contribution of the mitochondrial 
metabolism, we next assessed the ability of Abca1/Abcg1/ 
leukocytes to proliferate after treatment with membrane-
permeable antioxidants. Although glutathione monoethyl 
ester partially reduced the proliferation of all cells, tempol 
abrogated the enhanced proliferation of Abca1/Abcg1/ 
leukocytes (Fig. 4 H). Recently, Samudio et al. (2010) pro-
posed that leukemia cells uncouple fatty acid oxidation from 
ATP synthesis and rely on de novo fatty acid synthesis to sup-
port fatty acid oxidation. Consistent with this observation, 
pharmacological inhibition of carnitine palmitoyltransferase I 
(CPT-1) with etomoxir prevented the hyperproliferative 
response of Abca1/Abcg1/ leukocytes (Fig. 4 H). Finally, 
carnitine supplementation of the cells to promote mito-
chondrial efflux of excess acetyl moieties from both glu-
cose and fat oxidation (Muoio et al., 2012) prevented the 
higher proliferation rate of Abca1/Abcg1/ leukocytes 
(Fig. 4 H), providing additional evidence that the mito-
chondrial metabolism was responsible for the enhanced 
proliferation in Abca1/Abcg1/ leukocytes. Together, 
these findings showed that Abca1/Abcg1/ BM cells di-
rected the available glucose toward oxidative phosphory-
lation (Fig. 4 I), which could explain the enhanced glucose 
oxidation observed in Abca1/Abcg1/ BM transplanted 
mice (Fig. 1 E).
Glut1 inhibition prevents both IL-3–mediated  
myeloid proliferation and TLR4-mediated  
macrophage inflammatory response
The increased glucose conversion into lipids at basal or 
after IL-3 activation in Abca1/Abcg1/ leukocytes was 
abolished by Fasentin, a Glut1 inhibitor (Fig. 5 A; Wood 
et al., 2008), as was the proliferation of these cells (Fig. 5 B). 
Together, these findings suggest that IL-3R subunit sig-
naling enhances the Glut1-dependent glucose uptake of 
Abca1/Abcg1/ leukocytes to promote their proliferation. 
Enhanced glucose consumption and Glut1 expression were 
previously observed in macrophages during inflammatory 
responses (Fukuzumi et al., 1996; Gamelli et al., 1996). Con-
sistent with the previously observed enhancement in Toll-like 
receptor signaling in Abca1/Abcg1/ macrophages (Yvan-
Charvet et al., 2008), analysis of the rates of [14C]glucose 
oxidation in vitro in BM-derived macrophages revealed that 
in basal and LPS-stimulated conditions, Abca1/Abcg1/ 
macrophages exhibited a higher glucose consumption that was 
associated with increased Glut1 mRNA levels (not depicted). 
Interestingly, Glut1 inhibition by Fasentin reduced the inflam-
matory response induced by LPS in Abca1/Abcg1/ mac-
rophages (Fig. 5 C). Although the mRNA levels of Hk2 
and glucose-6-phosphate dehydrogenase followed the in-
flammatory pattern (Fig. 5 D), glycolytic genes such as PFK 
and ACL were barely affected by LPS in either WT or 
Abca1/Abcg1/ macrophages (Fig. 5 D). This contrasted 
with proliferating Abca1/Abcg1/ leukocytes (Fig. 4 I). 
Thus, Abca1/Abcg1/ macrophages could contribute 
not only to the enhanced glucose oxidation observed in 
Abca1/Abcg1/ BM transplanted mice (Fig. 1 E), but 
also to the local adipose tissue insulin resistance mediated by 
enhanced inflammatory response (Fig. 2 B). Together, these 
findings revealed that Glut1 controls both the proliferative 
and inflammatory status of Abca1/Abcg1/ leukocytes.
Both Glut1 inhibition and ApoA-I overexpression prevent 
fat loss in Abca1/Abcg1/ BM transplanted mice
We next explored the in vivo relevance of reducing the prolif-
eration and inflammatory status of myeloid cells through Glut1 
inhibition on the adipose tissue loss of Abca1/Abcg1/ BM 
chimeras. Mice that received WT or Abca1/Abcg1/ BM 
transduced with lentiviruses encoding Glut1 shRNA exhib-
ited a 1.6-fold reduction in Glut1 mRNA expression (not 
depicted) and a 20–30% reduction in the cell surface expres-
sion of Glut1 in their BM cells 7 wk after reconstitution, and 
this was sufficient to normalize the Glut1 cell surface expres-
sion to WT levels in Abca1/Abcg1/ BM transplanted 
mice (Fig. 5 E). This was associated with normalization of 
the 2-NBDG uptake in Abca1/Abcg1/ BM leukocytes 
(Fig. 5 F) and with normalization of the leukocyte counts in 
these mice (Fig. 5 G). Remarkably, the adipose tissue loss of 
mice transplanted with Abca1/Abcg1/ BM was rescued 
by transduction with Glut1 shRNA lentiviral particles (Fig. 5 H). 
We previously reported that the myeloproliferative syndrome 
and inflammatory phenotype of Abca1/Abcg1/ BM chi-
meras was reversed by overexpression of the human apoA-I 
transgene (ApoA-ITg; Yvan-Charvet et al., 2008, 2010). We 
now show that overexpression of the human apoA-I trans-
gene also reversed fat loss in Abca1/Abcg1/ BM trans-
planted mice (Fig. 5 I). Additionally, the apoA-I transgene 
normalized Glut1 cell surface expression in Abca1/Abcg1/ 
BM cells (Fig. 5 J). Together, our results suggest that suppres-
sion of Glut1 in myeloproliferative disorders may represent a 
novel approach not only to treat leukocytosis but also associ-
ated adipose tissue loss. Additionally, we now show that the 
rescue of the myeloproliferative disease of Abca1/Abcg1/ 
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Figure 4. The IL-3R–dependent proliferation of Abca1/Abcg1/ leukocytes is driven by increased mitochondrial metabolism. (A–D) Effect 
of IL-3 treatment on glycolytic metabolites (glucose 6-phosphate/fructose 6-phosphate and fructose 1,6-diphosphate; A), citric acid metabolites 
(B), related mitochondrial products (GTP and FAD; C), and ATP/ADP ratio (D) in WT and Abca1/Abcg1/ BM cells determined by LC-MS. (E) SDH 
activity in these cells. Results are means ± SEM of cultures from three independent mice. *, P < 0.05 versus WT controls; §, P < 0.05 versus treat-
ment. (F) WT and Abca1/Abcg1/ BM cells were grown for 48 h in 20 mM glucose DMEM (DMEM rich) or low-glucose DMEM (DMEM poor) 
supplemented with 20 mM glucose or 20 mM galactose in the presence of IL-3. Proliferation rates were determined after 2-h [3H]thymidine pulse 
labeling. (G and H) BM cells were grown for 48 h in liquid culture containing 10% FBS IMDM in the presence of the indicated chemical compounds 
and IL-3. Proliferation rates were determined after 2-h [3H]thymidine pulse labeling. Results are means ± SEM of an experiment performed in triplicate.  
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hallmark of chronic inflammatory diseases such as chronic 
infection, cancer, and heart failure (Delano and Moldawer, 
2006), the underlying mechanisms remain poorly under-
stood, leading to a lack of effective therapy. Most of the 
emerging therapeutic approaches to prevent adipose tissue 
loss focus on reducing the elevated circulating cytokine levels 
(Argilés et al., 2011) in part because of their action on insulin 
resistance and fat mobilization (Delano and Moldawer, 2006; 
Das et al., 2011). However, traditional antiinflammatory ap-
proaches such as COX-2 inhibitors showed for instance lim-
ited effectiveness in reversing the metabolic abnormalities 
seen in cancer patients (Kumar et al., 2010). Thus, there is a 
crucial need to better understand the mechanisms of adipose 
loss in this state of chronic hypermetabolism. Using three dif-
ferent mouse models of myeloproliferative disorders, includ-
ing two models based on expression of human leukemia 
disease alleles (Flt3-ITD and Mpl-W515L), we uncovered a 
glucose steal mechanism by which proliferating and inflam-
matory myeloid cells take up and oxidize glucose during the 
feeding period, contributing to energy dissipation and sub-
sequent loss of adipose mass. This reflected in part increased 
numbers of proliferating myeloid cells and tissues infiltrated 
with inflammatory myeloid cells.
Although only partially understood, there is a relationship 
between leukemia-causing genes and cellular energy metabo-
lism as the survival and proliferation of leukemic cells may re-
quire glucose for de novo lipid biosynthesis (DeBerardinis 
et al., 2008; Lunt and Vander Heiden, 2011). The increased 
glucose utilization in hyperproliferating Abca1/Abcg1/ 
BM myeloid cells resulted in part from a Ras-dependent up-
regulation of Glut1 expression in response to enhanced IL-3 
signaling (Flier et al., 1987; Yvan-Charvet et al., 2010). Simi-
larly, Mpl and Flt3 are receptor tyrosine kinases coupled to Ras 
signaling, and activating mutations in these receptors (Kelly 
et al., 2002; Pikman et al., 2006) were shown to cause higher 
Glut1 expression. In this context, it is tempting to parallel our 
myeloproliferative mouse models with other cancer models in 
which malignant cells rely on high levels of aerobic glycolysis 
as the major source of ATP to fuel cellular proliferation, known 
as the Warburg effect (Vander Heiden et al., 2009). However, 
the classical view of the Warburg effect, which involves defect 
in mitochondrial oxidative phosphorylation, has been recently 
challenged, and mitochondrial metabolism may indeed be 
functional in different types of tumor cells (Jose et al., 2011). 
We now provide both in vitro and in vivo evidence for in-
creased mitochondrial potential in leukocytes of our mouse 
(Yvan-Charvet et al., 2010) was in part associated with re-
duced Glut1 levels on leukocytes and prevented their adi-
pose loss.
ApoA-I overexpression prevents the increased glucose 
oxidation and adipose tissue atrophy in Flt3-ITD and  
Mpl-W515L mutant–mediated myeloproliferative disorders
As altered high-density lipoprotein (HDL) cholesterol ho-
meostasis has been previously observed in myeloprolifera-
tive disorders (Fiorenza et al., 2000; Westerterp et al., 
2012), we further tested whether the increased glucose 
oxidation and associated adipose tissue atrophy observed 
in Abca1/Abcg1/ BM transplanted mice could be ob-
served as a more general phenotype in other mouse models of 
myeloproliferative disorders and whether overexpression of 
the human apoA-I transgene would still be an efficient thera-
peutic in these models. The Flt3-ITD and Mpl-W515L al-
leles have been identified in patients with acute myeloid 
leukemia and myelofibrosis, respectively, and confer a fully 
penetrant myeloproliferative disorder in mice (Kelly et al., 
2002; Pikman et al., 2006). Accordingly, mice that received 
BM transduced with retroviruses encoding Flt3-ITD or Mpl-
W515L exhibited massive myeloid expansion compared with 
control retrovirus (Fig. 6, A and B), an effect which was par-
tially reversed by overexpression of the human ApoA-I trans-
gene (Fig. 6, A and B). We also observed epididymal fat 
mass atrophy and reduced plasma leptin levels in both models 
(Fig. 6 C and not depicted, respectively). Massive leukocyte 
infiltration was also observed in their adipose tissue (not de-
picted). Similar to Abca1/Abcg1/ BM transplanted mice, 
these features were associated with an increased RQ during 
the dark phase (Fig. 6, D and E), reflecting an 20% increase 
in glucose oxidation during this period (Fig. 6 F). Interest-
ingly, Mpl-W515L and Flt3-ITD mutant leukocytes exhib-
ited a significant increase in Glut1 cell surface expression 
(Fig. 6 G). Remarkably, overexpression of the human ApoA-I 
transgene not only prevented the fat mass loss (Fig. 6 C) of 
mice bearing the Mpl-W515L and Flt3-ITD mutations, but 
also significantly reversed the increased Glut1 cell surface ex-
pression in Mpl-W515L and Flt3-ITD leukocytes (Fig. 6 G) 
that was associated with increased RQ (Fig. 6, H and I) and 
glucose oxidation during the feeding period (Fig. 6 F).
DISCUSSION
Although there is growing evidence that weight loss, and 
especially the loss of muscle and adipose tissue mass, is a 
(I) Scheme illustrating the induction of glycolysis through modulation of plasma membrane cholesterol by ABCA1 and ABCG1 deficiency and 
increased mitochondrial metabolism that produces ATP and synthesizes lipids for cell growth. Lack of these transporters promotes growth fac-
tors dependent on IL-3R signaling–mediated glycolysis as reflected by (a) enhanced Hk2 and PFKp mRNA expression, (b) enhanced glycolytic 
metabolites content, (c) enhanced glucose oxidation (i.e., conversion into CO2), and (d) reversal of enhanced glucose oxidation by removal of cel-
lular cholesterol by cyclodextrin. The pyruvate generated through glycolysis is directed into the TCA cycle and increases mitochondrial metabolism 
as reflected by (a) enhanced mRNA expression of fumarase and SDHb, (b) enhanced SDH activity, (c) enhanced mitochondrial metabolites and 
mitochondrial membrane potential (H+), and (d) enhanced ATP/ADP ratio. Increased lipid synthesis was also observed in Abca1/Abcg1/  
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metabolism of fatty acids (i.e., fats burn in the fire of car-
bohydrates; Samudio et al., 2010). Although the mechanisms 
orchestrating this phenomenon remain to be investigated, 
it appears unlikely to be mediated by triglyceride or ce-
ramide biosynthesis. Interestingly, the antiproliferative effect 
model of myeloproliferative disorder. Surprisingly, not only 
inhibition of PDPs but also inhibition of CPT-1 prevented 
the proliferation of Abca1/Abcg1/ leukocytes. This em-
phasizes a scenario in which high rates of aerobic glycolysis 
in leukemia cells are necessary to support the mitochondrial 
Figure 5. Inhibition of Glut1 or overexpression of the human apoA-I transgene rescues adipose atrophy in Abca1/Abcg1/ BM chimeras. 
(A) Effect of IL-3 treatment on [14C]glucose conversion into lipids in WT and Abca1/Abcg1/ BM cells in the presence or absence of 50 µM fasentin, a 
Glut1 inhibitor. (B) Effect of Fasentin on IL-3–mediated proliferation in WT and Abca1/Abcg1/ BM cells. (C and D) Effect of Fasentin on LPS-mediated 
inflammatory (C) and glycolytic (D) responses in WT and Abca1/Abcg1/ BM-derived macrophages. Values were normalized to ribosomal 18S. Results 
are means ± SEM of three independent experiments performed in triplicate. *, P < 0.05 versus WT mice; §, P < 0.05 versus LPS treatment. (E and F) Quanti-
fication of Glut1 cell surface expression (E) and 2-NBDG uptake by flow cytometry (F) in CD45+ leukocytes isolated from the BM of WT recipients mice 
transplanted with WT or Abca1/Abcg1/ BM transduced with a lentivirus encoding Glut1 shRNA 7 wk after reconstitution. (G and H) Peripheral leuko-
cyte counts (G) and epididymal fat mass (H) of these mice at the end of the experiment. (I and J) Histograms showing epididymal fat mass loss (I) and 
Glut1 cell surface expression (J) in CD45+ peripheral leukocytes in chow-fed transgenic recipient mice overexpressing the human apoA-I transgene trans-
planted with Abca1/Abcg1/ BM. Results are ± SEM of an experiment of four to six animals per group. *, P < 0.05 versus WT recipients transplanted 
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Figure 6. HDL prevents the adipose tissue atrophy and enhanced glucose oxidation caused by Mpl-W515L and Flt3-ITD activating muta-
tions. (A) Representative dot plots and quantification of the splenic myeloid cells (CD115+ monocytes and CD115Gr1+ neutrophils) of WT and ApoA-I 
transgenic recipient mice transplanted with Mpl-W515L– and Flt3-ITD–transduced BM cells. (B and C) Quantification of the myeloid cells (B) and epididy-
mal fat mass (C) of these mice. (D, E, F, H, and I) RQ measured by indirect calorimetry (D, E, H, and I) and quantification of the nocturnal glucose oxidation 
of these mice (F). (G) Quantification of the cell surface expression of Glut1 in CD45+ leukocytes of these mice. Results are mean ± SEM of an experiment 
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leukocytes, reduced glucose oxidation during the feeding pe-
riod, and prevented adipose tissue loss.
In conclusion, our study elucidates a glucose steal mecha-
nism by proliferating and inflammatory myeloid cells that 
contributes to depletion of adipose tissue in myeloprolifera-
tive disorders. This mechanism involved enhanced glucose 
oxidation by myeloid cells that led to energy dissipation with 
consequences on fat storage. Inhibition of glucose uptake by 
leukocytes with a Glut1 inhibitor or by treatments that in-
crease HDL levels could ultimately provide new therapeutic 
approaches not only to limit cell proliferation but also to pre-
vent the energy imbalance and fat atrophy observed in my-
eloproliferative disorders and in other human malignancies.
MATERIALS AND METHODS
Mice and treatments. WT, Abca1/, Abcg1/, and Abca1/Abcg1/ 
littermates in a mixed C57BL/6 × DBA background (Yvan-Charvet et al., 
2007) were used for this study. Human apoA-1 transgenic (hapoA-1Tg) mice 
were obtained from the Jackson Laboratory. BM transplantation into the ge-
netically uniform F1 generation obtained by crossing C57BL/6 WT, hapoA-1Tg 
mice with WT DBA mice (The Jackson Laboratory) was performed as pre-
viously described (Yvan-Charvet et al., 2007). Animal protocols were ap-
proved by the Institutional Animal Care and Use Committee of Columbia 
University. Animals had ad libitum access to both food and water.
HSC transplantation. HSC transplantation was adapted from a previ-
ously described protocol (Wagers et al., 2002). In brief, congenic CD45.1+ 
B6.SJL-Ptprca—Pep3b-/BoyJ were purchased from the Jackson Labora-
tory and used to isolate Sca-1–depleted BM cells by FACS sorting. HSCs 
were isolated by FACS sorting of lineage-depleted BM from WT and 
Abca1/Abcg1/ backcrossed for 10 generations on a C57/BL6 back-
ground, based on the following cell surface markers: c-kit and Sca-1 (LSK, 
LinSca+c-kit+). Lethally irradiated WT recipients were i.v. injected with 
106 cells containing a mixture of CD45.1+ Sca-1–depleted BM cells and 
CD45.2+ LSK cells from either WT or Abca1/Abcg1/ mice in the ratio 
1:2,000. Transplanted recipients were screened by flow cytometry for re-
constitution of CD45.2+ leukocytes in peripheral blood at 6 wk after trans-
plant. More than 90% of leukocytes stained for the congenic marker CD45.2, 
thereby confirming the engraftment of LSK cells (Wagers et al., 2002).
Retroviral BM transplantation. The retroviral BM transplant assay was 
performed as previously described (Pikman et al., 2006). In brief, control, 
Mpl-W515L and Flt3-ITD retroviral supernatants were titered and used to 
transduce WT BM cells. In independent experiments, premade control and 
Glut1 shRNA lentiviral particles (Santa Cruz Biotechnology, Inc.) were 
used to transduce WT and Abca1/Abcg1/ BM cells. BM cells were cul-
tured for 24 h in transplantation media (RPMI + 10% FBS + 6 ng/ml IL-3, 
10 ng/ml IL-6, and 10 ng/ml stem cell factor) and treated by spin infection 
with retroviral supernatants (1 ml supernatant per 4 × 106 cells in the pres-
ence of polybrene) and centrifuged at 1,800 g for 90 min. The spin infection 
was repeated 24 h later. After washing, the cells were used for BM transplan-
tation into lethally irradiated WT recipient mice.
Energy expenditure. Metabolic activity was performed by in vivo indi-
rect open circuit calorimetry at the Mouse Phenotyping Core of Columbia 
University using a CaloSys calorimetry system (TSE Systems, Inc). Ani-
mals were placed into experimental chambers with free access to food and 
water for a 4-d consecutive period. Food intake was recorded with an au-
tomated feeding monitor system through the study period. Constant air-
flow (0.5 liter/min) was drawn through the chamber and monitored by a 
mass-sensitive flow meter. To calculate oxygen consumption (VO2), carbon 
dioxide production (VCO2), and RQ (ratio of VCO2 to VO2), gas con-
centrations were monitored at the inlet and outlet of the scaled chambers. 
of carnitine suggested that prevention of oxidative phos-
phorylation by efflux of excess mitochondrial acetyl moi-
eties (Muoio et al., 2012) might represent a novel strategy for 
the treatment of hematological malignancies. In conclusion, 
increased glucose oxidation and mitochondrial metabolism–
dependent proliferation of myeloid cells likely contributed 
to energy dissipation and subsequent loss of adipose mass.
Leukocytes and adipocytes can communicate through in-
teraction between secreted inflammatory cytokines and their 
cognate receptors (Lumeng and Saltiel, 2011; Odegaard and 
Chawla, 2011). The finding that highly infiltrated adipose 
depots were associated with impaired Glut4 translocation to 
the plasma membrane in response to insulin in Abca1/ 
Abcg1/ BM chimeras was strongly implied by prior studies 
indicating insulin resistance in peripheral tissues secondary to 
increased tumor-derived cytokines (Delano and Moldawer, 
2006). Nevertheless, these findings provide strong evidences 
that local inflammation driving adipose tissue insulin resis-
tance is not restricted to a role on fat mobilization in cancer-
associated adipose tissue loss (Das et al., 2011). This suggests 
that myeloproliferative cells develop efficient strategies to 
divert glucose from its expected destination, i.e., fat storage 
as a mean to meet their energetic needs. In part, this could 
be related to a shunt of glucose to the pentose phosphate 
pathway that has been recently shown to modulate the in-
flammatory response of activated immune cells (Ham, M., 
et al. 2008. The FASEB Journal Meeting. Abstr. 615.1; Blagih 
and Jones, 2012). This could ultimately contribute not only 
to the enhanced glucose oxidation observed in our mouse 
models of myeloproliferative disorders but also to the local 
adipose tissue insulin resistance mediated by enhanced in-
flammatory response.
Finally, we showed that Glut1 blockade prevented both 
basal and IL-3–induced proliferation of Abca1/Abcg1/ 
leukocytes in vitro and prevented LPS-induced inflammatory 
cytokine response in Abca1/Abcg1/ macrophages. This 
translated in vivo into the rescue of leukocytosis and adipose 
tissue infiltration of Abca1/Abcg1/ BM transplanted mice 
in response to Glut1 inhibition. Remarkably, this prevented 
the adipose tissue loss of these mice, confirming the key 
role of myeloid Glut1 in the diversion of energy stores from 
adipose to myeloid cells. Similarly, overexpression of the 
human ApoA-I transgene, previously shown to raise plasma 
HDL levels and prevent the myeloproliferative syndrome of 
Abca1/Abcg1/ BM transplanted mice (Yvan-Charvet 
et al., 2010), reduced Glut1 cell surface expression in leuko-
cytes and prevented their fat loss. This reflected in part the 
removal of excess cholesterol from plasma membrane in 
Abca1/Abcg1/ myeloid cells that prevented the IL-3R 
signaling (Yvan-Charvet et al., 2010) and subsequent in-
crease in Glut1-dependent glucose uptake (Fig. 3 G). These 
findings were further extended in two mouse models of my-
eloproliferative disorders based on expression of human leu-
kemia disease alleles (Flt3-ITD and Mpl-W515L) in which 
overexpression of the human ApoA-I transgene reduced my-
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(GK1.5), CD8b (53-6.7), CD19 (eBio1D3), CD45R (B220, RA3-6B2), 
Gr-1 (Ly6G, RB6-8C5), Cd11b (Mac1, M1/70), Ter119 (Ly76) and 
NK1.1 (Ly53, PK136), c-Kit (CD117, ACK2), and Sca-1 (D7) were all 
purchased from eBioscience. Glut1-FITC antibody was purchased from 
R&D Systems. These antibodies were used to sort HSCs and stain for leu-
kocytes in peripheral blood and tissues.
BM harvest and treatment. Primary BM cells were resuspended in 
IMDM (Gibco) containing 10% FCS (STEMCELL Technologies) and cul-
tured for 1 h in tissue culture flasks to remove adherent cells, including mac-
rophages. Suspended cells were then cultured for 72 h in the presence of 6 ng/ml 
IL-3 (R&D Systems). In some experiments, the farnesyl transferase inhibitor 
(EMD Millipore) was used at the final concentration of 1 µM, fasentin 
(Sigma-Aldrich) at 50 µM, DL-AP3 (Tocris Bioscience) at 50 µM, myriocin 
(Sigma-Aldrich) at 10 µM, diglyceride acyltransferase inhibitor (EMD Milli-
pore) at 40 µM, etomoxir (Sigma-Aldrich) at 40 µM, branched-chain amino 
acids (leucine, isoleucine, and valine; Sigma-Aldrich) at 1 mM, glutathione 
monoethyl ester (EMD Millipore) at 10 mM, tempol (EMD Millipore) at 
4 mM, and carnitine (Sigma-Aldrich) at 1 mM. For proliferation assays, 
cells were pulsed for 2 h with 2 µCi/ml [3H]thymidine, and the radioac-
tivity incorporated into the cells was determined by standard procedures 
using a liquid scintillation counter. In one experiment (Fig. 4 F), cells 
were resuspended in 20 mM glucose DMEM (DMEM rich; Gibco) or 
low-glucose DMEM (DMEM poor; Gibco) supplemented with 20 mM 
glucose or 20 mM galactose (Sigma-Aldrich) and cultured for 48 h in the 
presence of 6 ng/ml IL-3. SDH activity was determined by an ELISA 
kit according to the manufacturer’s instructions (MitoSciences). BM- 
derived macrophages were isolated and cultured in 10% FBS in DMEM 
supplemented with M-CSF for 5–10 d before the experiment. Where 
indicated, macrophages were incubated with 100 ng/ml LPS (Escherichia 
coli 0111:B4; Sigma-Aldrich).
Glucose metabolism experiments. Isolated BM cells were cultured for 
24 h with or without 6 ng/ml IL-3 and 50 µM fasentin, a Glut1 inhibitor. 
Where indicated, BM cells were differentiated into macrophages as described 
above. Cells were next incubated with 5.5 mM [14C]glucose in 2% BSA 
Krebs-Ringer bicarbonate buffer, pH 7.4. After 2 h, the generated 14CO2 
and the 14C incorporation into lipids were quantified as previously described 
(Yvan-Charvet et al., 2005). In some experiments, cellular cholesterol was 
depleted by 5 mM cyclodextrin for 1 h before growth factor treatment as 
previously described (Yvan-Charvet et al., 2010).
Directed metabolomic experiments. Isolated BM cells (106 cells) were 
cultured with or without 6 ng/ml IL-3 for 24 h. The next day, suspended 
cells were centrifuged at 1,000 rpm for 5 min, and pellets were rapidly 
washed (less than 10 s) with a mass spectrometry–compatible buffer (150 mM 
ammonium acetate solution) to prevent the presence of sodium and phos-
phate in the residue and limit interference with LC-MS analyses. After a sec-
ond step of centrifugation, pellets were immediately frozen in liquid nitrogen 
to quench metabolism according to the University of Michigan Molecular 
Phenotyping Core facility’s instructions. Samples were shipped on dry ice to 
the Molecular Phenotyping Core facility where metabolites were extracted 
by exposing the cells to a chilled mixture of 80% methanol, 10% chloroform, 
and 10% water. Glycolytic and citric acid metabolites were then analyzed by 
the Molecular Phenotyping Core facility using LC-MS as previously de-
scribed (Yuneva et al., 2012).
Western blot analysis. 2-h-fasted mice were administrated insulin i.p. 
(0.4 U/mouse). After 5 min, freshly isolated adipose tissue was homoge-
nized as previously described (Yvan-Charvet et al., 2005), and cell ex-
tracts were either directly used to measure phospho-Akt (clone 587F11; 
Cell Signaling Technology) by Western blot analysis or fractionated by 
differential centrifugation to isolate plasma membranes and low-density 
microsomes (Yvan-Charvet et al., 2010) and quantify Glut4 expression 
(clone 1F8; R&D Systems).
Total metabolic rate (energy expenditure) was calculated from oxygen 
consumption and carbon dioxide production using Lusk’s equation and 
expressed as watts per kilogram to the 0.75 power of body weight (Yvan-
Charvet et al., 2005). Glucose and lipid oxidation were calculated as previ-
ously described (Yvan-Charvet et al., 2005).
In vivo 2-[14C]-DG uptake. Uptake of 2-[14C]-DG in peripheral tissues 
was measured as previously described (Rofe et al., 1988). In brief, 2 µCi 
2-[14C]-DG was i.v. injected, and blood samples were collected at 5, 10, 20, 
30, and 40 min. Blood glucose was monitored through the study period 
with a glucometer (Roche). After 40 min, adipose tissue, skeletal muscle, 
heart, lung, spleen, and brain were rapidly dissected, weighed, and homog-
enized with 5% HClO4 solution. BM cells were collected from leg bones, 
and peripheral leukocytes were obtained after RBC lysis. The radioactivity 
incorporated in both 2-[14C]-DG and its 6-phosphate derivative was mea-
sured in the HClO4 extract and expressed as total radioactivity per tissue 
weight. The rate constant of net tissue uptake of 2-[14C]-DG was calculated 
as described previously (Rofe et al., 1988). In brief, the relative glucose 
uptake was calculated by dividing the area under the blood 2-[14C]-DG 
disappearance curve (cpm/min/ml) to the steady-state glucose concentra-
tion (mM) multiplied by the tissue 2-[14C]-DG (cpm/g tissue or cpm/106 
cells for the BM) at 40 min.
Blood parameters. Plasma leptin and insulin were determined by ELISA 
(Mouse Leptin Quantikine ELISA kit [R&D Systems]; Mouse insulin ELISA kit 
[Crystal Chem, Inc.]). Plasma TNF was measured by Luminex assay (Cytokine 
Core Laboratory). Blood glucose was assayed with a glucometer (Roche).
Histopathology. Mice were euthanized in accordance with the American 
Veterinary Association Panel of Euthanasia. Adipose tissue was serially paraf-
fin sectioned and stained with hematoxylin and eosin (H&E) for morpho-
logical analysis as previously described (Yvan-Charvet et al., 2007).
Adipose tissue cellularity. Cellularity of epididymal adipose tissue was 
determined as previously described (Yvan-Charvet et al., 2005). In brief, 
images of isolated adipocytes were acquired from a light microscope 
(IX-70; Olympus) fitted with a charge-coupled device camera (RS Photo-
metrics), and the measurement of 400 cell diameters was performed allow-
ing calculation of a mean fat cell weight. Tissue triglyceride content was 
measured from a sample of adipose tissue using a commercial kit (Sigma-
Aldrich). Fat cell number was estimated by dividing the tissue lipid content 
by the fat cell weight.
Glucose tolerance tests. After 6 h of fasting, mice were injected i.p. with 
d-glucose (2 g/kg of body weight), and blood samples were obtained by tail 
bleeding at 0, 15, 30, 60, 90, and 120 min after injection (Yvan-Charvet 
et al., 2005). Blood glucose was assayed with a glucometer (Roche).
Flow cytometry analysis. BM cells were collected from leg bones or 
spleen, lysed to remove RBCs, and filtered before use. Freshly isolated cells 
were stained with the appropriate antibodies for 30 min on ice. For periph-
eral blood leukocytes analysis, 100 µl blood was collected into EDTA tubes 
before RBC lysis, filtration, and staining for 30 min on ice. To assess the up-
take of 2-NBDG, prestained peripheral blood leukocytes (Yvan-Charvet 
et al., 2010) were incubated with 10 µM 2-NBDG (Invitrogen) for 30 min, 
followed by flow cytometric detection of fluorescence produced by the cells 
(Zou et al., 2005). The mitochondrial membrane potential was analyzed 
with 25 nM fluorescent TMRE (AnaSpec) staining for 30 min on prestained 
leukocytes. Viable cells, gated by light scatter or exclusion of CD45 cells, 
were analyzed on a four-laser LSRII cell analyzer (BD) or sorted on a FAC-
SAria Cell Sorter (BD), both running with DiVa software (BD). Data were 
analyzed using FlowJo software (Tree Star).
Antibodies. Anti–mouse CD45 (clone 30F11), CD115 (AFS98), TCR- 
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